Vir Biotechnology/$VIR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vir Biotechnology
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Ticker
$VIR
Sector
Primary listing
Employees
408
Headquarters
Website
VIR Metrics
BasicAdvanced
$695M
-
-$4.01
1.28
-
Price and volume
Market cap
$695M
Beta
1.28
52-week high
$14.45
52-week low
$4.16
Average daily volume
1.4M
Financial strength
Current ratio
7.006
Quick ratio
5.821
Long term debt to equity
9.858
Total debt to equity
9.858
Profitability
EBITDA (TTM)
-554.708
Gross margin (TTM)
-2,426.85%
Net profit margin (TTM)
-2,895.94%
Operating margin (TTM)
-2,946.17%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-24.45%
Return on equity (TTM)
-46.22%
Valuation
Price to revenue (TTM)
36.144
Price to book
0.73
Price to tangible book (TTM)
0.75
Price to free cash flow (TTM)
-1.472
Free cash flow yield (TTM)
-67.91%
Free cash flow per share (TTM)
-3.396
Growth
Revenue change (TTM)
-75.91%
Earnings per share change (TTM)
11.91%
3-year revenue growth (CAGR)
-79.19%
3-year earnings per share growth (CAGR)
-20.27%
What the Analysts think about VIR
Analyst ratings (Buy, Hold, Sell) for Vir Biotechnology stock.
Bulls say / Bears say
Held $1.02 billion in cash, cash equivalents, and investments as of March 31, 2025, ensuring funding for core programs and strategic priorities into mid-2027 (Vir IR)
Enrolled the first patient in the ECLIPSE Phase 3 registrational program for chronic hepatitis delta in Q1 2025, advancing a first-in-class combination with Breakthrough and Fast Track designations (Vir IR)
Continued to escalate dosing of dual-masked PRO-XTEN T-cell engagers VIR-5818 (HER2) and VIR-5500 (PSMA), with early safety data confirmed and Phase 1 for VIR-5525 (EGFR) set to start in H2 2025 (BioSpace)
Total revenue dropped 94.6% to $3.0 million in Q1 2025, down from $56.4 million a year earlier, due to the expiration of GSK collaboration milestones and deferred revenue recognition (Vir IR)
Net loss increased to $121.0 million, or $0.88 per share, in Q1 2025 versus $65.3 million, or $0.48 per share, in Q1 2024, reflecting higher cash burn and increased R&D spending (Vir IR)
R&D expenses rose 18.5% year-over-year to $118.6 million in Q1 2025, driven by a $30 million payment to Alnylam and the launch of the Phase 3 ECLIPSE program, pressuring near-term profitability despite efforts to cut costs (Vir IR)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
VIR Financial Performance
Revenues and expenses
VIR Earnings Performance
Company profitability
VIR News
AllArticlesVideos
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Business Wire1 month ago
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
Business Wire1 month ago
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vir Biotechnology stock?
Vir Biotechnology (VIR) has a market cap of $695M as of September 14, 2025.
What is the P/E ratio for Vir Biotechnology stock?
The price to earnings (P/E) ratio for Vir Biotechnology (VIR) stock is 0 as of September 14, 2025.
Does Vir Biotechnology stock pay dividends?
No, Vir Biotechnology (VIR) stock does not pay dividends to its shareholders as of September 14, 2025.
When is the next Vir Biotechnology dividend payment date?
Vir Biotechnology (VIR) stock does not pay dividends to its shareholders.
What is the beta indicator for Vir Biotechnology?
Vir Biotechnology (VIR) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.